Signal-averaged P wave reflects change in atrial electrophysiological substrate afforded by verapamil following cardioversion from atrial fibrillation

PACE - Pacing and Clinical Electrophysiology

Volumn 29, Issue 10, 2006, Pages 1089-1095

  Redfearn, Damian P ^a   Skanes, Allan C ^a   Lane, Joanne ^b   Stafford, Peter J ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Atrial fibrillation; Cardioversion; Signal averaged P wave; Verapamil

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; VERAPAMIL;

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HUMAN; MALE; OPEN STUDY; P WAVE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIGNAL AVERAGED ELECTROCARDIOGRAPHY; SINUS RHYTHM; TREATMENT OUTCOME;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COMBINED MODALITY THERAPY; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; HEART ATRIA; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VERAPAMIL;

EID: 33750046902     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2006.00469.x     Document Type: Article

References (36)

1. Tieleman RG, De Langen C, Van Gelder IC, de Kam PJ, Grandjean J, Bel KJ, Wijffels MC, et al. Verapamil reduces tachycardiainduced electrical remodeling of the atria. [see comments.]. Circulation 1997; 95:1945-1953.
2. De Simone A, Stabile G, Vitale DF, Turco P, Di Stasio M, Petrazzuoli F, Gasparini M, D et al. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. Journal of the American College of Cardiology 1999; 34:810-814.
3. De Simone A, De Pasquale M, De Matteis C, Canciello M, Manzo M, Sabino L, Alfano F, et al. VErapamil Plus Antiarrhythmic drugs Reduce Atrial Fibrillation recurrences after an electrical cardioversion (VEPARAF Study). Eur Heart J 2003; 24:1425-1429.
4. Botto GL, Belotti G, Ciro A, Ziacchi. (Abstract) Role of Verapamil in Atrial Fibrillation: Effect on Trigger or on Substrate? Data from the VeRAF Study. J Am Coll Cardiol 2002; 39(5):82A-83A.
5. Lindholm C-JA, Fredholm O, Moller SJ, Edvardsson N, Kronvall T, Pettersson T, Firsovaite V, et al. Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil. Heart 2004; 90:534-538.
6. Van Noord T, Van Gelder IC, Tieleman RG, Bosker HA, Tuinenburg AE, Volkers C, Veeger NJ, et al. VERDICT: The Verapamil versus Digoxin Cardioversion Trial: A randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. [see comments.]. Journal of Cardiovascular Electrophysiology 2001; 12:766-769.
7. Meurling CJ, Ingemansson MP, Roijer A, Carlson J, Lindholm CJ, Smideberg B, Sornmo L, et al. Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil. Europace 1999; 1:234-241.
8. Ramanna H, Elvan A, Wittkampf FH, de Bakker JM, Hauer RN, Robles dME. Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation. Journal of the American College of Cardiology 2001; 37:1403-1407.
9. Daoud EG, Hummel JD, Augostini R, Williams S, Kalbfleisch SJ. Effect of verapamil on immediate recurrence of atrial fibrillation. Journal of Cardiovascular Electrophysiology 2000; 11:1231-1237.
10. Elesber AA, Rosales AG, Shen WK, Malouf JF, Hodge DO, Ammash NM, Chandrasekaran K, et al. Noninvasive assessment of acute changes in atrial electrophysiology after cardioversion by signal-averaged P-wave electrocardiography. Pacing Clin Electrophysiol 2005; 28:135-139.
11. Gencel L, Poquet F, Gosse P, Haissaguerre M, Marcus FI, Clementy J. Correlation of signal-averaged P wave with electrophysiological testing for atrial vulnerability in strokes of unexplained etiology. Pacing & Clinical Electrophysiology 1994; 17:2118-2124.
12. Healey JS, Theoret-Patrick P, Green MS, Lemery R, Birnie D, Tang AS. Reverse atrial electrical remodelling following atrial defibrillation as determined by signal-averaged ECG. Can J Cardiol 2004; 20:311-315.
13. Redfearn DP, Lane J, Ward K, Stafford PJ. High-resolution analysis of the surface p wave as a measure of atrial electrophysiological substrate. Ann Noninvasive Electrocardiol 2006; 11:12-19.
14. Michelucci A, Bagliani G, Colella A, Pieragnoli P, Porciani MC, Gensini G, Padeletti L. P wave assessment: State of the art update. Card Electrophysiol Rev 2002; 6:215-220.
15. Zeng C, Wei T, Zhao R, Wang C, Chen L, Wang L. Electrocardiographic diagnosis of left atrial enlargement in patients with mitral stenosis: The value of the P-wave area. Acta Cardiol 2003; 58:139-141.
16. Goyal SB, Spodick DH. Electromechanical dysfunction of the left atrium associated with interatrial block. Am Heart J 2001; 142:823-827.
17. Centurion OA, Isomoto S, Fukatani M, Shimizu A, Konoe A, Tanigawa M, Kaibara M, et al. Relationship between atrial conduction defects and fractionated atrial endocardial electrograms in patients with sick sinus syndrome. Pacing Clin Electrophysiol 1993; 16:2022-2033.
18. Keane D, Stafford PJ, Baker S, Lewis S, Jackson G, Vincent R. Signal-averaged electrocardiography of the sinus and paced Pwave in sinus node disease. Pacing & Clinical Electrophysiology 1995; 18:1346-1353.
19. Stafford PJ, Cooper J, De Bono DP, Vincent R, Garratt CJ. Effect of low dose sotalol on the signal averaged P wave in patients with paroxysmal atrial fibrillation. British Heart Journal 1995; Vol 74:640.
20. Stafford PJ, Robinson D, Vincent R. Optimal analysis of the signal averaged P wave in patients with paroxysmal atrial fibrillation. British Heart Journal 1995; Vol 74:418.
21. Yamaguchi I, Obayashi K, Mandel WJ. Electrophysiological effects of verapamil. Cardiovascular Research 1978; 12:597-608.
22. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation 1996; 94:2968-2974.
23. Lee SH, Yu WC, Cheng JJ, Hung CR, Ding YA, Chang MS, Chen SA. Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation 2000; 101:200-206.
24. Michelucci A, Padeletti L, Chelucci A, Mezzani A, Porciani MC, Caruso F, Lebrun E, et al. Influence of age, lead axis, frequency of arrhythmic episodes, and atrial dimensions on P wave triggered SAECG in patients with lone paroxysmal atrial fibrillation. Pacing & Clinical Electrophysiology 1996; 19:758-767.
25. Kurita Y, Mitamura H, Shiroshita-Takeshita A, Yamane A, Ieda M, Kinebuchi O, Sato T, et al. Daily oral verapamil before but not after rapid atrial excitation prevents electrical remodeling. Cardiovasc Res 2002; 54:447-455.
26. Zipes DP, Jalife J. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, Pennsylvania: Saunders, 2004, 19106.
27. Buchanan JW Jr, Saito T, Gettes LS. The effects of antiarrhythmic drugs, stimulation frequency, and potassium-induced restingmembrane potential changes on conduction velocity and dV/dtmax in guinea pig myocardium. Circ Res 1985; 56:696-703.
28. Gaspo R, Bosch RF, Bou-Abboud E, Nattel S. Tachycardia-Induced Changes in Na+ Current in a Chronic Dog Model of Atrial Fibrillation. Circ Res 1997; 81:1045-1052.
29. Guidera SA, Steinberg JS. The signal-averaged P wave duration: A rapid and noninvasive marker of risk of atrial fibrillation [see comments]. Journal of the American College of Cardiology 1993; 21:1645-1651.
30. Morillo CA, Klein GJ, Jones DL, Guiraudon CM. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995; 91:1588-1595.
31. Daoud EG, Knight BP, Weiss R, Bahu M, Paladino W, Goyal R, Man KC, et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997; 96:1542-1550.
32. Duff HJ, Offord J, West J, Catterall WA. Class I and IV antiarrhythmic drugs and cytosolic calcium regulate mRNA encoding the sodium channel alpha subunit in rat cardiac muscle. Mol Pharmacol 1992; 42:570-574.
33. Yu WC, Lee SH, Tai CT, Tsai CF, Hsieh MH, Chen CC, Ding YA, et al. Reversal of atrial electrical remodeling following cardioversion of long-standing atrial fibrillation in man. Cardiovascular Research 1999; 42:470-476.
34. Stafford PJ, Kamalvand K, Tan K, Vincent R, Sulke N. Prediction of maintenance of sinus rhythm after cardioversion of atrial fibrillation by analysis of serial signal-averaged Pwaves. Pacing & Clinical Electrophysiology 1998; 21:1387-1395.
35. Spurrell P, Stafford PJ, Kamalvand K, Sulke N. (Abstract) The signal averaged P wave: A non-invasive marker for atrial remodeling following DC cardioversion of atrial fibrillation in man? Pacing & Clinical Electrophysiology 1999; 22(Suppl):890.
36. Zardo F, Antonini-Canterin F, Brieda M, Hrovatin E, Pavan D, Burelli C, Cervesato E, et al. Can short-term verapamil therapy reduce the recurrence of atrial fibrillation after successful low energy intracardiac cardioversion? Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 2001; 2:513-518.